Latest Acelot News & Updates

See the latest news and media coverage for Acelot. We track all announcements, press releases, and industry mentions in real time, all in one place.

Acelot

Clinical-stage biotechnology company developing treatments for neurodegenerative diseases

acelot.com

Headquarters: South San Francisco, United States
Company type: Private company
Number of employees: 10–30
Industry: Pharmaceuticals

Last updated October 26

Latest news about Acelot

In short: Acelot began Phase Ia dosing for ACE-2223 in ALS and presented preclinical TDP-43 data.

Company announcements

October 26 Acelot

Acelot presents TDP-43 data at NEALS meeting

CMO Mark Forman presents preclinical findings on ACE-2223 while CEO Katie Planey joins a panel on therapeutic targets.

September 17 Acelot

Acelot initiates Phase Ia trial for ALS drug ACE-2223

The first-in-class oral small molecule targets aggregated TDP-43 in healthy adults to evaluate safety and pharmacokinetics.

August 12 Acelot

Acelot appoints Mark Forman as CDO and CMO

Dr. Forman joins to lead clinical development of ACE-2223 for ALS, bringing expertise from Ventyx Biosciences and Passage Bio.

October 1, 2025 Acelot

Acelot presents ACE-2223 progress at NEALS

CEO Dr. Katie Planey speaks on October 8th at 2pm ET in Florida. Poster 151 follows on October 9th. FIH trials start next year.

Media coverage

October 26 Yahoo Finance

Acelot to Present on TDP-43 Targeting in ALS at 2026 NEALS Meeting

Acelot, a biotechnology company developing small molecule therapies for challenging targets in diseases with high unmet need, today announced that Acelot CMO & CDO Mark...

October 13 American City Business Journals

Startup Acelot takes a swing at deadly, devastating Lou Gehrig's disease

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The company this month said it started dosing volunteers...

September 17 BioSpace

Acelot Announces Initiation of Dosing in Phase Ia Clinical Trial of ACE-2223, a First-in-Class Oral Small Molecule Targeting Aggregated TDP-43 in Amyotrophic Lateral Sclerosis ...

ACE-2223 is the first clinical-stage small molecule for ALS designed to directly target and disrupt aggregated TDP-43. SAN FRANCISCO--(BUSINESS WIRE)--Acelot, a biotechnology company developing small...

August 12 BioSpace

Acelot Announces Appointment of Mark Forman, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer

Seasoned neuroscientist with extensive translational experience advancing early-stage clinical assets joins Acelot to support the continued development of ACE-2223 targeting TDP-43 for the treatment ...

Never miss news about Acelot

Track Acelot and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Acelot competitors & trending companies

Browse news for competitors to Acelot and other trending companies.